Nicht-24-Stunden-Schlaf-Wach- Syndrom (Non-24)

PETER YOUNG; CLAUDIA SCHILLING; INGO FIETZE

doi:10.1055/s-0038-1626183

Schlaf, Table of Contents

Schlaf 2017; 06(04): 202-213
DOI: 10.1055/s-0038-1626183

Review

Schattauer GmbH

Nicht-24-Stunden-Schlaf-Wach- Syndrom (Non-24)

PETER YOUNG

¹Klinik für Schlafmedizin und Neuromuskuläre Erkrankungen, Universitätsklinikum Münster, Email: Peter.Young@ukmuenster.de

,

CLAUDIA SCHILLING

²Zentralinstitut für Seelische Gesundheit, Klinik für Psychiatrie und Psychotherapie, Email: Claudia.Schilling@zi-mannheim.de

,

INGO FIETZE

³Zentrum für Schlafmedizin Charité, Universitätsmedizin Berlin, Email: Ingo.Fietze@charite.de

› Author Affiliations

Abstract

Die Behandlung von Schlafstörungen bei blinden Erwachsenen erfolgte bislang meist symptomatisch. Ein seit 2016 zugelassener Melatonin-Rezeptoragonist ermöglicht nun eine zeitlich präzise und zielgerichtete Synchronisierung des zentralen Schrittmachers und demzufolge eine Anpassung des endogenen zirkadianen Schlaf-Wach-Rhythmus mit der 24-Stunden-Umgebung, was das primäre Ziel bei der Behandlung von Non-24 darstellt.

Full Text

References

Literatur
1 Sack RL, Lewy AJ, Blood ML, Keith LD, Nakagawa H. Circadian Rhythm Abnormalities in Totally Blind People: Incidence and Clinical Significance. The Journal of Clinical Endocrinology and Metabolism 1992; 75: 127-134.
2 Okawa M, Uchiyama M. Circadian Rhythm Sleep Disorders: Characteristics and Entrainment Pathology in Delayed Sleep Phase and Non-24-h Sleep-Wake Syndrome. Sleep Medicine Reviews 2007; 11: 485-496.
3 Sack RL, Auckley D, Auger RR. et al. Circadian Rhythm Sleep Disorders: Part I, Basic Principles, Shift Work and Jet Lag Disorders. An American Academy of Sleep Medicine Review. Sleep 2007; 30: 1460-1483.
4 Waller EA, Bendel RE, Kaplan J. Sleep Disorders and the Eye. Mayo Clinic Proceedings 2008; 83: 1251-1261.
5 Zhu L, Zee PC. Circadian rhythm sleep disorders. Neurol Clin 2012; 30 (04) 1167-1191.
6 Zisapel N. Circadian rhythm sleep disorders: pathophysiology and potential approaches to management. CNS Drugs 2001; 15 (04) 311-328.
7 Licamale L, Dressman M, Feeney J, Polymeropoulos MH. editors. Pleiomorphic Expression of N24HSWD in the Totally Blind. SLEEP 2012, the 26^th Annual Meeting of the APSS. 2012 June 09–13 2012. Boston, Massachusetts, USA: unpublished data.
8 Lockley SW, Skene DJ, Arendt J. Comparison Between Subjective and Actigraphic Measurement of Sleep and Sleep Rhythms. Journal of Sleep Research 1999; 8: 175-183.
9 Sack RL, Auckley D, Auger RR. et al. Circadian Rhythm Sleep Disorders: Part II, Advanced Sleep Phase Disorder, Delayed Sleep Phase Disorder, Free-Running Disorder and Irregular Sleep-Wake Rhythm. An American Academy of Sleep Medicine Review. Sleep 2007; 30: 1484-1501.
10 Remler O. Untersuchungen an Blinden über die 24-Stunden-Rhythmik. Monatsblaetter für Augenheilkunde 1948; 113: 116-137.
11 Deutsches Institut für Medizinische Dokumentation und Information (DIMDI). Kapitel VII – Krankheiten des Auges und der Augenanhangsgebilde (H00-H59). 2015 [Zuletzt aktualisiert; abgerufen am 27.05.2016]; Abrufbar unter: https://www.dimdi.de/static/de/klassi/icd-10-gm/kodesuche/onlinefassungen/htmlgm2015/blockh53-h54.htm
12 Bertram B. Blindheit und Sehbehinderung in Deutschland: Ursachen und Häufigkeit. Der Augenarzt 2005; 39: 267-268.
13 Lu BS, Zee PC. Circadian Rhythm Sleep Disorders. Chest 2006; 130: 1915-1923.
14 Lockley SW, Dijk DJ, Kosti O, Skene DJ, Arendt J. Alertness, Mood and Performance Rhythm Disturbances Associated With Circadian Sleep Disorders in the Blind. Journal of Sleep Research 2008; 17: 207-216.
15 Fietze I, Young P, Niessen C, Erler T. Non-24: Eine unterschätzte zirkadiane Schlafstörung bei Blinden. Somnologie 2016; 20: 119-124.
16 Waller EA, Bendel RE, Kapin J. Sleep disorders and the eye. Mayo Clin Proc 2008; 83 (11) 1251-1261.
17 Garaulet M, Ordovas JM, Madrid JA. The Chronobiology, Etiology and Pathophysiology of Obesity. International Journal of Obesity 2010; 34: 1667-1683.
18 Rüger M, Scheer FA. Effects of Circadian Disruption on the Cardiometabolic System. Reviews in Endocrine & Metabolic Disorders 2009; 10: 245-260.
19 Uchiyama M, Lockley SW. Non-24-Hour Sleep-Wake Syndrome in Sighted and Blind Patients. Sleep Medicine Clinics 2009; 4: 195-211.
20 Gallagher A, Levedan C. editors. A National Registry of Totally Blind Individuals With Sleep-Wake Complaints. SLEEP 2012, the 26^th Annual Meeting of the APSS. 2012 June 09–13 2012. Boston, Massachusetts, USA: unpublished data.
21 Karatsoreos IN. Effects of Circadian Disruption on Mental and Physical Health. Current Neurology and Neuroscience Reports 2012; 12: 218-225.
22 Buxton OM, Cain SW, O‘Connor SP. et al. Adverse Metabolic Consequences in Humans of Prolonged Sleep Restriction Combined with Circadian Disruption. Science Translational Medicine 2012; 4: 129-143.
23 Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse Metabolic and Cardiovascular Consequences of Circadian Misalignment. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 4453-4458.
24 Young ME, Bray MS. Potential Role for Peripheral Circadian Clock Dyssynchrony in the Pathogenesis of Cardiovascular Dysfunction. Sleep Medicine 2007; 8: 656-667.
25 Konturek PC, Brzozowski T, Konturek SJ. Gut Clock: Implication of Circadian Rhythms in the Gastrointestinal Tract. Journal of Physiology and Pharmacology 2011; 62: 139-150.
26 Wirz-Justice A. Biological Rhythm Disturbances in Mood Disorders. International Clinical Psychopharmacology 2006; 21 (Suppl. 01) 11-15.
27 Wright Jr. KP, Hull JT, Hughes RJ, Ronda JM, Czeisler CA. Sleep and Wakefulness out of Phase With Internal Biological Time Impairs Learning in Humans. Journal of Cognitive Neuroscience 2006; 18: 508-521.
28 Morgenthaler TI, Lee-Chiong T, Alessi C. et al. Practice Parameters for the Clinical Evaluation and Treatment of Circadian Rhythm Sleep Disorders. An American Academy of Sleep Medicine Report. Sleep 2007; 30: 1445-1459.
29 American Academy of Sleep Medicine. Circadian Rhythm Sleep-Wake Disorder. International Classification of Sleep Disorder. 3rd Edition 2014
30 Xcenda GmbH. Bericht der GKV-Routinedatenanalyse der Health Risk Institute (HRI)-Forschungsdatenbank. Analysis of Prevalence of Blindness and High-Grade Visual Impairment With Claims Data of the German Sickness Fund. 2015
31 Kushida C. Non-24-h Sleep–Wake Disorder (Free-Running Type, Nonentrained Type, Hypernychthemeral Syndrome) in Sighted and Blind Patients. The Encyclopedia of Sleep 2013; 34-40.
32 Flynn-Evans EE, Lockley SW. A Pre-Screening Questionnaire to Predict Non-24 Hour Sleep Wake Rhythm Disorder (N24HSWD) Among the Blind. Journal of Clinical Sleep Medicine 2016; 12: 703-710.
33 Flynn-Evans EE, Tabandeh H, Skene DJ, Lockley SW. Circadian Rhythm Disorders and Melatonin Production in 127 Blind Women With and Without Light Perception. Journal of Biological Rhythms 2014; 29: 214-220.
34 Lewy AJ, Newsome DA. Different Types of Melatonin Circadian Secretory Rhythms in Some Blind Subjects. The Journal of Clinical Endocrinology and Metabolism 1983; 56: 1103-1107.
35 Lockley SW, Dressman MA, Licamele L. et al. Tasimelteon for Non-24-Sleep-Wake Disorder in Totally Blind People (SET and RESET): Two Multicentre, Randomised, Double-Masked, Placebo-Controlled Phase 3 Trials. The Lancet 2015; 386: 1754-1764.
36 Skene DJ, Lockley SW, James K, Arendt J. Correlation Between Urinary Cortisol and 6-Sulphatoxymelatonin Rhythms in Field Studies of Blind Subjects. Clinical Endocrinology (Oxford) 1999; 50: 715-719.
37 Wright Jr. KP, Hughes RJ, Kronauer RE, Dijk DJ, Czeisler CA. Intrinsic Near-24-h Pacemaker Period Determines Limits of Circadian Entrainment to a Weak Synchronizer in Humans. Proceedings of the National Academy of Sciences 2001; 98: 14027-14032.
38 Lockley SW, Dressman MA, Licamele L. et al. Supplementary Appendix-Tasimelteon for Non-24-Sleep-Wake Disorder in Totally Blind People (SET and RESET): Two Multicentre, Randomised, Double-Masked, Placebo-Controlled Phase 3 Trials. The Lancet 2015; 386.
39 Leger D, Quera-Salva MA, Vecchierini MF. et al. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies. Expert Opinion on Drug Safety. Expert Opinion. Drug Safety. 2015 14. (11).
40 Leger D, Guilleminault C, Defrance R, Domont A, Paillard M. Prevalence of Sleep/Wake Disorders in Persons with Blindness. Clinical Science (London) 1999; 97: 193-199.
41 Tabandeh H, Lockley SW, Buttery R. et al. Disturbance of Sleep in Blindness. American Journal of Ophthalmology 1998; 126: 707-712.
42 Vanda Pharmaceuticals Inc. Dossier zur Nutzenbewertung gemäß §35a SGB V – Tasimelteon (Hetlioz®) Nicht-24-Stunden-Schlaf-Wach-Syndrom (Non-24) bei völlig blinden Erwachsenen. Modul 3 A. 2016
43 Vyas MV, Garg AX, Iansavichus AV. et al. Shift Work and Vascular Events: Systematic Review and Meta-Analysis. BMJ 2012; 345: e4800.
44 American Psychiatric Association. Circadian Rhythm Sleep-Wake Disorder. Diagnostic and Statistical Manual of Mental Disorders (DSM), 5th Edition. 2013
45 Deutsche Gesellschaft für Schlafforschung und Schlafmedizin D, Somnologie – Schlafforschung und Schlafmedizin. S3-Leitlinie – Nichterholsamer Schlaf/Schlafstörung. 2009
46 Arendt J, Rajaratnam SM. Melatonin and its Agonists: An Update. The British Journal of Psychiatry 2008; 193: 267-269.
47 Dubocovich ML, Markowska M. Functional MT1 and MT2 Melatonin Receptors in Mammals. Endocrine 2005; 27: 101-110.
48 Hardeland R, Poeggeler B. Melatonin and Synthetic Melatonergic Agonists: Actions and Metabolism in the Central Nervous System. Central Nervous System Agents Medicinal Chemistry 2012; 12: 189-216.
49 Dubocovich ML, Hudson RL, Sumaya IC, Masana MI, Manna E. Effect of MT1 Melatonin Receptor Deletion on Melatonin-Mediated Phase Shift of Circadian Rhythms in the C57BL/6 Mouse. Journal of Pineal Research 2005; 39: 113-120.
50 Liu C, Weaver DR, Jin X. et al. Molecular Dissection of Two Distinct Actions of Melatonin on the Suprachiasmatic Circadian Clock. Neuron 1997; 19: 91-102.
51 Johnsa JD, Neville MW. Tasimelteon: A Melatonin Receptor Agonist for Non-24-Hour Sleep-Wake Disorder. The Annals of Pharmacotherapy 2014; 48: 1636-1641.
52 Paulis L, Simko F, Laudon M. Cardiovascular Effects of Melatonin Receptor Agonists. Expert Opinion on Investigational Drugs 2012; 21: 1661-1678.
53 U.S. Food and Drug Administration (FDA). PCNS Drugs Advisory Committee. Tasimelteon: For the Treatment of Non-24 Hour Sleep-Wake Disorder in Blind Individuals Without Light Perception. 2013
54 Williams WP, McLin DE, Dressman MA, Neubauer DN. Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders. Pharmacotherapy 2016; 36 (09) 1028-1041.
55 Czeisler CA. Duration, timing and quality of sleep are each vital for health,performance and safety. Sleep Health – Journal of the National Sleep Foundation. Sleep Health 2015; 1: 5-8.
56 Committee on Sleep Medicine Research Board on Health Sciences Policy. Sleep disorders and sleep deprivation. An Unmet Public Health Problem. Washington, D.C.: Institute of Medicine of the National Academies; The National Academies Press; 2006
57 Buxton OM. et al. Adverse Metabolic Consequences in Humans of Prolonged Sleep Restriction Combined with Circadian Disruption. Sci Transl Med 2012; 4: 129ra43.
58 Wright Jr. KP, Hull JT, Hughes RJ. et al. Sleep and Wakefulness Out of Phase with Internal Biological Time Impairs Learning in Humans. J Cogn Neurosc 2006; 18: 508-521.
59 Gemeinsamer Bundesausschuss. Richtlinie des Gemeinsamen Bundesausschusses über die Verordnung von Arzneimitteln in der vertragsärztlichen Versorgung (Arzneimittel-Richtlinie/AM-RL). Fassung vom 18. Dezember 2008/22.Januar 2009, Bundesanzeiger 2009 Nr. 49a, zuletzt geändert am 18. August 2016, veröffentlicht im BAnz AT 29.09.2016 B2, in Kraft getreten am 30. September 2016.
60 Gemeinsamer Bundesausschuss. Richtlinie des Gemeinsamen Bundesausschusses über die Verordnung von Arzneimitteln in der vertragsärztlichen Versorgung (Arzneimittel-Richtlinie/AM-RL). Fassung vom 18. Dezember 2008/22.Januar 2009, Bundesanzeiger 2009 Nr. 49a, zuletzt geändert am 18. August 2016, veröffentlicht im BAnz AT 29.09.2016 B2, in Kraft getreten am 30. September 2016.
61 Gemeinsamer Bundesausschuss. Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie: Anlage III Nummer 32 – Hypnotika/Hypnogene oder Sedativa. Informationsarchiv des Gemeinsamen Bundesausschuss. 17. Dezember 2015